Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-17T15:27:32.237Z Has data issue: false hasContentIssue false

Importance of Control Group Selection for Evaluating Antimicrobial Use as a Risk Factor for Methicillin-Resistant Staphylococcus Aureus Bacteremia

Published online by Cambridge University Press:  21 June 2016

Erika J. Ernst*
Affiliation:
University of Iowa College of Pharmacy, Iowa City, Iowa
George Raley
Affiliation:
University of Iowa College of Pharmacy, Iowa City, Iowa
Loreen A. Herwaldt
Affiliation:
Department of Internal Medicine, the University of Iowa College of Medicine; and the University of Iowa Hospitals and Clinics, Iowa City, IowaDepartment of Epidemiology, the University of Iowa College of Public Health, Iowa City, Iowa
Daniel J. Diekema
Affiliation:
Department of Pathology, the University of Iowa College of Medicine; and the Veterans Affairs Medical Center, Iowa City, Iowa
*
University of Iowa, College of Pharmacy, S428 Pharmacy Building, Iowa City, IA 52242.erika-ernst@uiowa.edu

Abstract

Objective:

We investigated the importance of control group selection during an evaluation of antimicrobial use as a risk factor for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our institution.

Methods:

We performed a case-control study. A case was defined as any patient admitted between January 1997 and May 2001 who developed nosocomial MRSA bacteremia. We used two control groups; control group I consisted of patients with nosocomial methicillin-susceptible S. aureus (MSSA) bacteremia and control group II included only patients without bacteremia. We matched control-patients to case-patients using age, gender, time at risk, and hospital ward. Data collected on all patients included demographics, comorbidities, antibiotic use, time at risk, length of stay, severity of illness, and outcome.

Results:

We evaluated 63 patients (21 in each group). The three groups were well matched regarding age, gender, underlying diseases, and severity of illness. Patients in the MRSA group were more likely to have received a fluoroquinolone and had a higher mean number of days of fluoroquinolone use than did patients in the MSSA group (P = .027 and P = .015, respectively). However, all measures of fluoroquinolone use were similar for case-patients and for control-patients who did not have nosocomial bloodstream infection.

Conclusions:

Control group selection is important in evaluating antimicrobial use as a risk factor for MRSA bacteremia. Using control-patients infected with MSSA, rather than uninfected control-patients, may overestimate the association between antimicrobial use and MRSA infection. (Infect Control Hosp Epidemiol 2005;26:634-637)

Information

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable